The abscopal effect: a review of pre-clinical and clinical advances
Radiotherapy has been used for more than a hundred years to cure or locally control tumors.
Regression of tumors outside of the irradiated field was occasionally observed and is known …
Regression of tumors outside of the irradiated field was occasionally observed and is known …
Metastatic prostate cancer: treatment options
Abstract Background: Metastatic prostate cancer (PCa) is associated with considerable
diminished overall survival (OS). Standard treatment for metastatic PCa has long been …
diminished overall survival (OS). Standard treatment for metastatic PCa has long been …
[HTML][HTML] The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies
Context Despite the lack of level 1 evidence, metastasis-directed therapy (MDT) is used
widely in the management of metastatic prostate cancer (mPCa) patients. Data are …
widely in the management of metastatic prostate cancer (mPCa) patients. Data are …
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer …
Background Most patients with metastatic cancer eventually develop resistance to systemic
therapy, with some having limited disease progression (ie, oligoprogression). We aimed to …
therapy, with some having limited disease progression (ie, oligoprogression). We aimed to …
Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial
Importance Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1
(PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of …
(PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of …
The oligometastatic spectrum in the era of improved detection and modern systemic therapy
Metastases remain the leading cause of cancer-related mortality. The oligometastasis
hypothesis postulates that a spectrum of metastatic spread exists and that some patients …
hypothesis postulates that a spectrum of metastatic spread exists and that some patients …
Emerging evidence and treatment paradigm of non-small cell lung cancer
SYM Liu, MM Zheng, Y Pan, SY Liu, Y Li… - Journal of hematology & …, 2023 - Springer
Research on biomarker-driven therapy and immune check-point blockade in non-small cell
lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also …
lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also …
ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases
J van der Velden, J Willmann, M Spałek… - Radiotherapy and …, 2022 - Elsevier
After liver and lungs, bone is the third most common metastatic site (Nystrom et al., 1977).
Almost all malignancies can metastasize to the skeleton but 80% of bone metastases …
Almost all malignancies can metastasize to the skeleton but 80% of bone metastases …
Practical management of oligometastatic non–small-cell lung cancer
K Jasper, B Stiles, F McDonald… - Journal of Clinical …, 2022 - ascopubs.org
Local ablative therapies, including surgery or stereotactic radiotherapy (SABR), are
becoming an integral component in the treatment of oligometastatic disease in non–small …
becoming an integral component in the treatment of oligometastatic disease in non–small …
UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy
P Diez, GG Hanna, KL Aitken, N Van As, A Carver… - Clinical Oncology, 2022 - Elsevier
The use of stereotactic ablative radiotherapy (SABR) in the UK has expanded over the past
decade, in part as the result of several UK clinical trials and a recent NHS England …
decade, in part as the result of several UK clinical trials and a recent NHS England …